Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2015

View Archived Issues

[11C]PF-367: a promising PET tracer for neuroimaging of GSK-3

Phase I/IIa results disclosed for therapeutic p16 HPV vaccine

Sareum secures funding to investigate TYK2 inhibitors for T-ALL

INV-17, a RORgT inverse agonist, demonstrates complete survival in MRL/lpr mice

GenSpera receives grant from FDA OOPD to develop mipsagargin for glioblastoma

Synergy Pharmaceuticals reports phase III results for plecanatide in CIC

Merck & Co. discloses Nav1.7 sodium channel blockers

Chong Kung Dang presents GPR119 agonists

Kyorin introduces FPR2 agonists

Nektar Therapeutics discloses opioid agonists

Incyte develops BRD4 inhibitors

Actavis adopts Allergan name

Clinical benefit seen with autologous T cells specific for HER2 and CMV in glioblastoma multiforme

HemoShear changes name to reflect new focus on discovery of novel therapeutics

Biosimilar etanercept SB-4 found equivalent in phase III study in RA

Velicept to merge with AltheRx to advance development of solabegron

Merck KGaA's acquisition of Sigma-Aldrich cleared by EC and Chinese authorities

Lilly forges new oncology collaborations

FDA approves Ventana's companion diagnostic test for Xalkori

University of Queensland to lead project on MERS

Genentech and Almac Discovery to develop ubiquitin-specific protease inhibitors

Radius Health reports results from phase III trials of abaloparatide in osteoporosis

First clinical data of namilumab in patients with active RA

FORMA Therapeutics achieves milestones under agreements with Celgene and Boehringer Ingelheim

Improvement in growth velocity observed in phase II study of BMN-111 for achondroplasia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...